Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Phar... ( NEW YORK April 18 2011 /- Keryx Bioph...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical

Date:4/18/2011

NEW YORK, April 18, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia. Under the license agreement with JT/Torii, within 30 days, Keryx will receive a non-refundable milestone payment of $5 million from JT/Torii for the achievement of this milestone. Zerenex™ (ferric citrate), a ferric iron-based phosphate binder, is also in Phase 3 clinical development in the United States for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We congratulate our partner, JT/Torii, on the initiation of the Phase 3 program in Japan and are excited by their progress. We believe that this serves to further validate the commercial potential for Zerenex worldwide."

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex from Panion & BF Biotech, Inc.

Sublicense Agreement with Japan Tobacco & Torii PharmaceuticalIn September 2007, Keryx sublicensed to JT and Torii the exclusive rights for the development and commercialization of its hyperphosphatemia drug, Zerenex (ferric citrate), in Japan. The licensing arrangement calls for JT and Torii to pay to Keryx up to $100 million in up-front license fees and payments upon the achievement of specified milestones, of which $28 million has been received by Keryx to date. In addition, upon commercialization, JT and Torii will make royalty payments to Keryx on net sales of the drug in Japan. JT and Torii are responsible for all development and commercializat
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/23/2013)... TeamHealth Medical Call Center (THMCC), a premier ... lines, announces its newly formed Clinical Advisory Committee. ... leaders, provides clinical expertise to advance THMCC,s purpose ... hospital clients, physician clients and patients. ... imperative to continuously advance our services and improve ...

(Date:5/23/2013)... -- More than half of women diagnosed with early ... still have excellent outcomes. To educate women, Agendia, Inc. ... sources of online consumer information about breast cancer genomic ... recently diagnosed women with information sources, to help them ... "We anticipate these innovative social media campaigns will encourage ...

(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC. ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...

Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3 Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2 Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3

[0] TeamHealth Medical Call Center Forms Clinical Advisory Committee [0] Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions [0] Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog

... Dec. 13, 2011 More than 60,000 young children ... into medicine while their parents or caregivers were not ... of safe medicine storage, the Centers for Disease Control ... (CHPA) Educational Foundation, in partnership with the PROTECT ...

... 2011 Mirixa Corporation, the leader in pharmacy-based patient ... has joined the company as Vice President of Sales ... sales team and develop strategic partner relationships. ... most recently served as Vice President of Strategic Partnerships ...

Cached Medicine Technology:CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 2 CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight 3 Mirixa Names New VP of Sales and Business Development 2

CDC and CHPA Educational Foundation Launch Up and Away and Out of Sight Mirixa Names New VP of Sales and Business Development

(Date:5/23/2013)... May 23, 2013 Da Vinci surgical ... a trial in Washington State May 23, according to ... in surgical robot lawsuits , expresses disappointment in ... Vinci lawsuits to not read a single verdict as ... (Estate of Fred E. Taylor v. Intuitive Surgical Inc.; ...

(Date:5/23/2013)... News) -- People who eat at fast-food restaurants are ... teens are the worst offenders, a new study found. ... meals by as much as 34 percent, parents of ... adults by as much as 20 percent," study lead ... from the Robert Wood Johnson Foundation, which helped fund ...

(Date:5/23/2013)... 2013 “Talk. They Hear You.” a ... parents to talk to children as young as nine ... launched today by the Substance Abuse and Mental Health ... conjunction with SAMHSA’s 2013 National Prevention Week—an annual health ... substance abuse and mental health issues. , SAMHSA’s latest ...

(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...

(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...

Breaking Medicine News(10 mins):Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2 Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2 Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3 Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2 Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3

[0] Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial [0] How Many Calories in Your Fast-Food Meal? Guess Again [0] New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking [0] Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study [0] Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits

... Universal Health Services, Inc. (NYSE: UHS ) ... pay a cash dividend of $0.08 per share on ... June 1, 2009.Universal Health Services, Inc. is one of ... acute care and behavioral health hospitals, and ambulatory centers ...

... New grants will serve communities in outstate Minnesota ... of Directors approved four regional grants dedicated to ... and policy advocacy. The grants will provide resources ... new grant awards show our continuing commitment to ...

... Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical ... million in a second Series A financing extension ... was again led by Vivo Ventures. This capital ... development activities and strategic business objectives."Sagent,s business model ...

... The American Association for Homecare supports expanded anti-fraud efforts ... and the Department of Health and Human Services (HHS) ... two agencies outlined plans for expanding anti-fraud strike forces ... Care Fraud Prevention and Enforcement Action Team. Even ...

... dialysis patients, quality of life, study says , , WEDNESDAY, ... and the anti-clotting drug dipyridamole reduces blockages and extends ... for kidney dialysis, new research has found. , When ... stenosis -- a narrowing of blood vessels -- at ...

... to flu variant that circulated before 1957 , , WEDNESDAY, May ... immunity to the new H1N1 swine flu virus because of ... 1957, a U.S. infectious-disease expert said Wednesday. , "The further ... to have been exposed to H1N1 virus back before 1957, ...

Universal Health Services, Inc. Announces Dividend ClearWay Minnesota(SM) Board Approves Four Regional Grants Sagent Pharmaceuticals Announces Extension of Series A Financing American Association for Homecare Supports Expanded Federal Efforts by DOJ and HHS to Combat Medicare Fraud Drug Combo Keeps Kidney Artery-Vein Grafts Viable Older Adults May Have Some Immunity to Swine Flu

Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....

Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....

Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....

...

Medicine Products:

Silicone Strip (220 Style)Silicone Hemisphere (77G Style)Silicone Strip (20 Style)Vannas Capulotomy scissors curved